The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

Carmen Tur, Anne Laure Dubessy, Susana Otero-Romero, Maria Pia Amato, Tobias Derfuss, Franziska Di Pauli, Ellen Iacobaeus, Marcin Mycko, Hesham Abboud, Anat Achiron, Angelo Bellinvia, Alexey Boyko, Jean Laurent Casanova, David Clifford, Ruth Dobson, Mauricio F. Farez, Massimo Filippi, Kathryn C. Fitzgerald, Mattia Fonderico, Riadh GouiderYael Hacohen, Kerstin Hellwig, Bernhard Hemmer, Ludwig Kappos, Filipa Ladeira, Christine Lebrun-Frénay, Céline Louapre, Melinda Magyari, Matthias Mehling, Celia Oreja-Guevara, Lekha Pandit, Caroline Papeix, Fredrik Piehl, Emilio Portaccio, Isabel Ruiz-Camps, Krzysztof Selmaj, Steve Simpson-Yap, Aksel Siva, Per Soelberg Sorensen, Maria Pia Sormani, Maria Trojano, Adi Vaknin-Dembinsky, Sandra Vukusic, Brian Weinshenker, Heinz Wiendl, Alexander Winkelmann, María Isabel Zuluaga Rodas, Mar Tintoré, Bruno Stankoff

Research output: Contribution to journalArticlepeer-review

Abstract

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.

Original languageEnglish (US)
Pages (from-to)1424-1456
Number of pages33
JournalMultiple Sclerosis Journal
Volume28
Issue number9
DOIs
StatePublished - Aug 2022

Keywords

  • coronavirus disease 2019
  • COVID-19
  • disease-modifying treatment
  • DMT-associated infections
  • Multiple sclerosis
  • neuromyelitis optica spectrum disorder
  • progressive multifocal leukoencephalopathy
  • risk mitigation strategies
  • SARS-CoV-2

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021'. Together they form a unique fingerprint.

Cite this